NASDAQ : PCSA
Processa Pharmaceuticals, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 1.89 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 6.33M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 6.62M | 6.18M | 4.78M | 5.66M | 8.76M | 4.69M |
| Research & Development | 6.23M | 7.81M | 7.27M | 5.80M | 11.49M | 6.88M |
| Operating Expenses | 12.86M | 13.99M | 12.05M | 11.46M | 20.26M | 11.57M |
| Operating Income | -12.86M | -13.99M | -12.05M | -11.46M | -20.26M | -11.57M |
| Interest & Investment Income | 99.90K | 109.49K | 201.09K | 335.54K | 101.20K | 11.63K |
| Other Non Operating Income (Expenses) | -680.00K | 315.18K | ||||
| EBT Excluding Unusual Items | -13.44M | -13.56M | -11.85M | -11.12M | -20.16M | -11.56M |
| Asset Writedown | -7.27M | |||||
| Other Unusual Items | 163.77K | |||||
| Pretax Income | -13.44M | -13.56M | -11.85M | -11.12M | -27.42M | -11.96M |
| Income Tax Expense | -530.61K | |||||
| Net Income | -13.44M | -13.56M | -11.85M | -11.12M | -27.42M | -11.43M |
| Net Income to Common | -13.44M | -13.56M | -11.85M | -11.12M | -27.42M | -11.43M |
| Shares Outstanding (Basic) | 2.40M | 1.31M | 122.44K | 52.46K | 32.22K | 30.64K |
| Shares Outstanding (Diluted) | 2.40M | 1.31M | 122.44K | 52.46K | 32.22K | 30.64K |
| EPS (Basic) | -5.59 | -10.36 | -96.78 | -211.99 | -851.18 | -372.97 |
| EPS (Diluted) | -5.59 | -10.36 | -96.78 | -211.99 | -851.18 | -372.97 |
| Free Cash Flow | -11.97M | -11.39M | -11.25M | -8.07M | -9.61M | -8.72M |
| Free Cash Flow Per Share | -4.98 | -8.70 | -91.87 | -153.75 | -298.12 | -284.52 |
| EBITDA | -12.86M | -13.99M | -12.05M | -11.46M | -19.47M | -10.78M |
| D&A For EBITDA | 1.20K | 1.20K | 782.00 | 222.00 | 788.50K | 790.97K |
| EBIT | -12.86M | -13.99M | -12.05M | -11.46M | -20.26M | -11.57M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 196.32K | 5.54M | 1.19M | 4.71M | 6.50M | 16.50M |
| Cash & Short-Term Investments | 196.32K | 5.54M | 1.19M | 4.71M | 6.50M | 16.50M |
| Other Receivables | 70.27K | |||||
| Receivables | 70.27K | |||||
| Prepaid Expenses | 1.40M | 133.92K | 687.83K | 926.30K | 1.88M | 1.76M |
| Other Current Assets | 472.00K | |||||
| Total Current Assets | 2.07M | 5.67M | 1.88M | 5.63M | 8.39M | 18.33M |
| Property, Plant & Equipment | 3.21K | 3.81K | 75.69K | 148.61K | 227.59K | 74.18K |
| Other Intangible Assets | 8.06M | |||||
| Other Long-Term Assets | 2.14M | 1.27M | 5.54K | 5.54K | 5.54K | |
| Total Assets | 2.07M | 7.81M | 3.23M | 5.79M | 8.62M | 26.46M |
| Accounts Payable | 1.66M | 1.06M | 880.88K | 311.62K | 327.55K | 218.91K |
| Accrued Expenses | 727.47K | 1.18M | 578.73K | 146.27K | 403.06K | 279.26K |
| Current Portion of Leases | 73.02K | 83.65K | 78.90K | 71.08K | ||
| Other Current Liabilities | 189.04K | 189.05K | 401.77K | |||
| Total Current Liabilities | 2.39M | 2.24M | 1.53M | 730.58K | 998.56K | 971.02K |
| Long-Term Leases | 487.00 | 66.91K | 150.55K | 7.38K | ||
| Total Liabilities | 2.39M | 2.24M | 1.53M | 797.48K | 1.15M | 978.40K |
| Common Stock | 279.00 | 257.00 | 15.00 | 129.00 | 80.00 | 1.57K |
| Additional Paid-In Capital | 107.11M | 106.66M | 89.22M | 80.66M | 72.02M | 62.31M |
| Retained Earnings | -107.43M | -100.78M | -87.22M | -75.37M | -64.25M | -36.82M |
| Treasury Stock | -300.00K | -300.00K | -300.00K | -300.00K | ||
| Shareholders' Equity | -317.34K | 5.58M | 1.70M | 4.99M | 7.47M | 25.49M |
| Total Liabilities & Equity | 2.07M | 7.81M | 3.23M | 5.79M | 8.62M | 26.46M |
| Total Debt | 73.51K | 150.55K | 229.45K | 78.46K | ||
| Net Cash (Debt) | 196.32K | 5.54M | 1.12M | 4.56M | 6.27M | 16.42M |
| Net Cash Per Share | 0.08 | 4.23 | 9.13 | 86.84 | 194.73 | 535.89 |
| Filing Date Shares Outstanding | 2.79M | 2.66M | 210.77K | 114.24K | 49.12K | 31.69K |
| Total Common Shares Outstanding | 2.79M | 2.57M | 148.10K | 51.44K | 32.07K | 31.42K |
| Working Capital | -320.55K | 3.43M | 346.52K | 4.90M | 7.39M | 17.36M |
| Book Value Per Share | -0.11 | 2.17 | 11.45 | 96.99 | 232.94 | 811.11 |
| Tangible Book Value | -317.34K | 5.58M | 1.70M | 4.99M | 7.47M | 17.43M |
| Tangible Book Value Per Share | -0.11 | 2.17 | 11.45 | 96.99 | 232.94 | 554.69 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -13.44M | -13.56M | -11.85M | -11.12M | -27.42M | -11.43M |
| Depreciation & Amortization | 1.20K | 1.20K | 782.00 | 222.00 | 788.50K | 790.97K |
| Other Amortization | 115.61K | |||||
| Asset Writedown & Restructuring Costs | 7.27M | 300.00K | ||||
| Stock-Based Compensation | 614.66K | 857.55K | 629.51K | 1.06M | 8.83M | 3.41M |
| Other Operating Activities | 716.32K | -224.50K | 87.18K | 1.39M | 274.52K | -610.00K |
| Change in Accounts Receivable | 70.27K | 6.75K | ||||
| Change in Accounts Payable | 873.68K | 175.92K | 569.26K | -15.93K | 108.64K | -101.79K |
| Change in Other Net Operating Assets | -739.20K | 1.37M | -681.67K | 621.14K | 364.69K | -1.08M |
| Operating Cash Flow | -11.97M | -11.39M | -11.25M | -8.06M | -9.61M | -8.72M |
| Capital Expenditures | -3.24K | -2.78K | ||||
| Other Investing Activities | -1.16M | -850.00K | ||||
| Investing Cash Flow | -1.16M | -850.00K | -3.24K | -2.78K | ||
| Long-Term Debt Repaid | -6.60K | -5.20K | ||||
| Net Debt Issued (Repaid) | -3.75K | -6.60K | -5.20K | |||
| Issuance of Common Stock | 6.40M | 16.60M | 7.76M | 6.32M | 10.05M | |
| Repurchase of Common Stock | -320.00 | -10.40K | -24.46K | -52.75K | -388.84K | -64.40K |
| Other Financing Activities | -186.49K | |||||
| Financing Cash Flow | 6.40M | 16.58M | 7.73M | 6.27M | -388.84K | 9.80M |
| Net Cash Flow | -6.74M | 4.35M | -3.51M | -1.80M | -9.99M | 1.08M |
| Free Cash Flow | -11.97M | -11.39M | -11.25M | -8.07M | -9.61M | -8.72M |
| Free Cash Flow Per Share | -4.98 | -8.70 | -91.87 | -153.75 | -298.12 | -284.52 |
| Levered Free Cash Flow | -8.74M | -6.55M | -5.85M | -4.11M | -2.96M | -4.19M |
| Unlevered Free Cash Flow | -8.74M | -6.55M | -5.85M | -4.11M | -3.08M | -4.19M |
| Cash Interest Paid | 14.05K | 5.61K | 1.20K | |||
| Change in Working Capital | 134.49K | 1.54M | -112.40K | 605.21K | 543.60K | -1.18M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 6.33M | 6.53M | 2.89M | 8.24M | 17.59M | 77.01M |
| Enterprise Value | 6.14M | 216.99K | 92.69K | 1.55M | 8.78M | 58.01M |
| Last Close Price | 1.89 | 2.88 | 22.09 | 167.30 | 550.00 | 2,450.00 |
| PB Ratio | 1.17 | 1.70 | 1.65 | 2.35 | 3.02 | |
| P/TBV Ratio | 1.17 | 1.70 | 1.65 | 2.35 | 4.42 | |
| Debt / Equity Ratio | 0.04 | 0.03 | 0.03 | 0.00 | ||
| Net Debt / Equity Ratio | 0.62 | -0.99 | -0.66 | -0.91 | -0.84 | -0.64 |
| Net Debt / EBITDA Ratio | 0.01 | 0.40 | 0.09 | 0.40 | 0.32 | 1.52 |
| Net Debt / FCF Ratio | 0.02 | 0.49 | 0.10 | 0.56 | 0.65 | 1.88 |
| Quick Ratio | 0.08 | 2.48 | 0.78 | 6.44 | 6.51 | 17.06 |
| Current Ratio | 0.87 | 2.54 | 1.23 | 7.71 | 8.40 | 18.87 |
| Return on Equity (ROE) | -464.20% | -372.97% | -354.51% | -178.52% | -166.43% | -47.20% |
| Return on Assets (ROA) | -156.78% | -158.34% | -167.08% | -99.41% | -72.17% | -27.98% |
| Return on Capital Employed (ROCE) | 4,051.80% | -250.80% | -710.30% | -226.60% | -265.80% | -45.40% |
| Earnings Yield | -296.02% | -207.86% | -410.42% | -134.94% | -155.91% | -14.84% |
| FCF Yield | -188.98% | -174.47% | -389.58% | -97.87% | -54.61% | -11.32% |
| Buyback Yield / Dilution | -652.98% | -969.33% | -133.38% | -62.83% | -5.16% | -104.27% |